Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rejuveinix in critical limb ischemia
NCT03041259Phase 2Unknown
- Sponsor
- Reven Pharmaceuticals
- Start
- Jan 2020
- Primary completion
- Jan 2022
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
01
Overview
Phase 2, randomised, double-blind trial of rejuveinix in critical limb ischemia (CLI) and Peripheral Arterial Disease (PAD) (2 arms), sponsored by Reven Pharmaceuticals. Primary endpoint: Major Adverse Events at 84 days. Status: unknown.
02
Drugs
rejuveinix
03
Conditions
critical limb ischemia (CLI)Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT03041259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03041259.